Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBIT (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EBIT for 6 consecutive years, with -$5.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT fell 287.34% year-over-year to -$5.6 million, compared with a TTM value of -$40.4 million through Dec 2025, down 96.77%, and an annual FY2025 reading of -$40.4 million, down 96.77% over the prior year.
  • EBIT was -$5.6 million for Q4 2025 at Cytek Biosciences, up from -$9.2 million in the prior quarter.
  • Across five years, EBIT topped out at $3.8 million in Q2 2021 and bottomed at -$15.0 million in Q1 2025.
  • Average EBIT over 5 years is -$4.1 million, with a median of -$3.3 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 924.35% in 2023, then soared 2279.56% in 2024.
  • Year by year, EBIT stood at $1.3 million in 2021, then tumbled by 93.62% to $84000.0 in 2022, then crashed by 263.1% to -$137000.0 in 2023, then skyrocketed by 2279.56% to $3.0 million in 2024, then plummeted by 287.34% to -$5.6 million in 2025.
  • Business Quant data shows EBIT for CTKB at -$5.6 million in Q4 2025, -$9.2 million in Q3 2025, and -$10.6 million in Q2 2025.